Learn about our healthcare areas

Explore medicine and therapy products
Explore MedTech products

Find our latest news, stories and press releases

Delivering long-term value for our stakeholders

Explore career opportunities and more

Impacting health for humanity

Search Results

No Results

    Recently Viewed

      Listening...

      Sorry, I don't understand. Please try again
      1. Home/
      2. Media Center/
      3. Press releases /
      4. Innovative Medicine

      Innovative Medicine

      Innovative Medicine
      September 30, 2014

      Johnson & Johnson Announces Agreement To Acquire Alios BioPharma

      Acquisition Strengthens Existing Pipeline in Viral Diseases
      Learn more
      Innovative Medicine
      September 24, 2014

      Study Observed Association between JANSSEN® CONNECT® Injection Centers and Increased Adherence to Healthcare Provider-Ordered Janssen Long-Acting Treatment for People with Schizophrenia

      JANSSEN® CONNECT® program seeks to provide people living with schizophrenia information and assistance to support healthcare provider-ordered long-acting antipsychotic treatment
      Learn more
      Innovative Medicine
      September 12, 2014

      Johnson & Johnson Announces New Grant to Harvard Medical School to Combat Drug-Resistant Tuberculosis

      New collaboration will help address significant global unmet needs in pediatric drug-resistant tuberculosis (DR-TB) treatment and optimize use of existing DR-TB treatments
      Learn more
      Global Health Equity
      September 3, 2014

      Johnson & Johnson Responds to Ebola Crisis with Commitment to Accelerate Vaccine Program in Collaboration with the US National Institutes of Health (NIH) and Provide Humanitarian Relief Aid

      Learn more
      Innovative Medicine
      September 2, 2014

      New Data Show Once-Daily XARELTO® May Be an Alternative to Vitamin K Antagonists in Treating Atrial Fibrillation Patients Undergoing Elective Cardioversion

      X-VeRT Study Results Presented as a Hot Line Session at the ESC Congress 2014 and Published in European Heart Journal
      Learn more
      Research
      August 29, 2014

      Janssen Expands EXPLORER Global Cardiovascular Research Program to Evaluate the Role of XARELTO® in Addressing Critical Medical Needs

      New Studies Grow XARELTO® Clinical Development Program to More Than 275,000 Patients
      Learn more
      Research
      August 26, 2014

      Janssen Diagnostics Expands Research Portfolio to Include Next-Generation Sequencing

      Enhanced Offering to Enable ‘Dynamic Monitoring’ in Cancer Research
      Learn more
      Innovative Medicine
      August 25, 2014

      Janssen Affiliate Cilag GmbH International Acquires Covagen AG

      Clinical Candidate COVA 322 and FynomAb® Technology Platform Further Strengthen Immunology Portfolio and Capabilities
      Learn more
      Innovative Medicine
      August 8, 2014

      U.S. FDA Approves INVOKAMET™ (canagliflozin/metformin HCl) for the Treatment of Adults with Type 2 Diabetes

      In Phase 3 studies, INVOKANA® plus metformin lowered blood sugar and reduced secondary endpoints of body weight and systolic blood pressure to a greater degree than metformin alone
      Learn more
      Load more